Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.83
TRIB's Cash-to-Debt is ranked lower than
68% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. TRIB: 0.83 )
Ranked among companies with meaningful Cash-to-Debt only.
TRIB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.98 Max: No Debt
Current: 0.83
Equity-to-Asset 0.44
TRIB's Equity-to-Asset is ranked lower than
53% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. TRIB: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
TRIB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.7 Max: 0.88
Current: 0.44
0.29
0.88
Piotroski F-Score: 3
Altman Z-Score: 2.19
WACC vs ROIC
7.77%
-17.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -40.00
TRIB's Operating Margin % is ranked higher than
67% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. TRIB: -40.00 )
Ranked among companies with meaningful Operating Margin % only.
TRIB' s Operating Margin % Range Over the Past 10 Years
Min: -56.78  Med: 12.17 Max: 67.5
Current: -40
-56.78
67.5
Net Margin % -101.02
TRIB's Net Margin % is ranked higher than
56% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. TRIB: -101.02 )
Ranked among companies with meaningful Net Margin % only.
TRIB' s Net Margin % Range Over the Past 10 Years
Min: -101.02  Med: 13.49 Max: 67.4
Current: -101.02
-101.02
67.4
ROE % -52.62
TRIB's ROE % is ranked higher than
52% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. TRIB: -52.62 )
Ranked among companies with meaningful ROE % only.
TRIB' s ROE % Range Over the Past 10 Years
Min: -76.72  Med: 9.84 Max: 54.77
Current: -52.62
-76.72
54.77
ROA % -29.83
TRIB's ROA % is ranked higher than
55% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. TRIB: -29.83 )
Ranked among companies with meaningful ROA % only.
TRIB' s ROA % Range Over the Past 10 Years
Min: -45.03  Med: 7.27 Max: 41.2
Current: -29.83
-45.03
41.2
ROC (Joel Greenblatt) % -59.80
TRIB's ROC (Joel Greenblatt) % is ranked higher than
57% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. TRIB: -59.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TRIB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -123.61  Med: 28.4 Max: 125.23
Current: -59.8
-123.61
125.23
3-Year Revenue Growth Rate -3.30
TRIB's 3-Year Revenue Growth Rate is ranked lower than
67% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. TRIB: -3.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TRIB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -30.9  Med: -0.45 Max: 78.4
Current: -3.3
-30.9
78.4
GuruFocus has detected 4 Warning Signs with Trinity Biotech PLC $TRIB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TRIB's 10-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

TRIB Guru Trades in Q1 2016

Chuck Royce 799,098 sh (+13.73%)
Jim Simons 194,150 sh (-3.92%)
» More
Q2 2016

TRIB Guru Trades in Q2 2016

Chuck Royce 779,098 sh (-2.50%)
Jim Simons 162,550 sh (-16.28%)
» More
Q3 2016

TRIB Guru Trades in Q3 2016

Jim Simons 237,450 sh (+46.08%)
Chuck Royce 439,130 sh (-43.64%)
» More
Q4 2016

TRIB Guru Trades in Q4 2016

Chuck Royce 293,330 sh (-33.20%)
Jim Simons 135,950 sh (-42.75%)
» More
» Details

Insider Trades

Latest Guru Trades with TRIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:NAS:MGEN, NAS:QTNT, NAS:RDNT, NAS:ONVO, NAS:SRDX, OTCPK:CLIFF, NAS:OXFD, NAS:FLGT, OTCPK:CBIS, NAS:PACB, OTCPK:EPGNF, AMEX:SENS, NAS:TTOO, NAS:CTSO, NAS:FLDM, NAS:AIQ, NAS:NVDQ, NYSE:ENZ, NAS:VRML, NAS:PMD » details
Traded in other countries:TRBA.Germany,
Headquarter Location:Ireland
Trinity Biotech PLC develops, acquires, manufactures & markets medical diagnostic products for clinical laboratory & point-of-care of diagnostic market. Its products are used to detect autoimmune, infectious, diabetes and disorders of liver & intestine.

Trinity Biotech PLC was incorporated as a public limited company, registered in Ireland in January 1992. The Company commenced operations in 1992 and, in October 1992, completed an initial public offering of its securities in USA. The Company develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. Its products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. It is also a provider of raw materials to the life sciences industry. The Company markets its portfolio of almost 850 products to customers in approximately 100 countries around the world through its own sales force and a network of international distributors and strategic partners. The primary market for Trinity Biotech's tests remains the USA. The Company develops, acquires, manufactures and markets clinical in-vitro diagnostic products. It supplies the clinical laboratory segment of the in-vitro diagnostic market. It also sells raw materials to the life sciences industry. Its Point-of-Care product is Unigold (tm), which tests for the presence of HIV antibodies. It sells its product through its own direct sales-force in four countries: the United States, Germany, France and the United Kingdom. Its competitors are Abbott Diagnostics, Alere Inc., Arkray, Bio-Rad, Diasorin Inc., Euroimmun, Johnson & Johnson, OraSure Technologies Inc., Phadia, Roche Diagnostics, Siemens (from the combined acquisitions of Bayer, Dade-Behring and DPC), Thermo Fisher, Tosoh and Werfen. The preclinical and clinical testing, manufacture, labelling, distribution, and promotion of Trinity Biotech's products are subject to extensive and rigorous government regulation in the United States and in other countries in which its products are sought to be marketed.

Ratios

vs
industry
vs
history
PB Ratio 1.21
TRIB's PB Ratio is ranked higher than
96% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. TRIB: 1.21 )
Ranked among companies with meaningful PB Ratio only.
TRIB' s PB Ratio Range Over the Past 10 Years
Min: 0.23  Med: 1.39 Max: 3.56
Current: 1.21
0.23
3.56
PS Ratio 1.62
TRIB's PS Ratio is ranked higher than
78% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. TRIB: 1.62 )
Ranked among companies with meaningful PS Ratio only.
TRIB' s PS Ratio Range Over the Past 10 Years
Min: 0.16  Med: 2.54 Max: 7.02
Current: 1.62
0.16
7.02
Price-to-Operating-Cash-Flow 15.85
TRIB's Price-to-Operating-Cash-Flow is ranked higher than
80% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. TRIB: 15.85 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TRIB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.84  Med: 17.36 Max: 442.86
Current: 15.85
1.84
442.86
EV-to-EBIT -7.73
TRIB's EV-to-EBIT is ranked higher than
65% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. TRIB: -7.73 )
Ranked among companies with meaningful EV-to-EBIT only.
TRIB' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.73  Med: 15.1 Max: 75.8
Current: -7.73
-7.73
75.8
EV-to-EBITDA -7.73
TRIB's EV-to-EBITDA is ranked lower than
59% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. TRIB: -7.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
TRIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.73  Med: 15.1 Max: 75.8
Current: -7.73
-7.73
75.8
Current Ratio 5.28
TRIB's Current Ratio is ranked higher than
84% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. TRIB: 5.28 )
Ranked among companies with meaningful Current Ratio only.
TRIB' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 2.71 Max: 8.63
Current: 5.28
1
8.63
Quick Ratio 3.99
TRIB's Quick Ratio is ranked higher than
82% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. TRIB: 3.99 )
Ranked among companies with meaningful Quick Ratio only.
TRIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.45  Med: 1.44 Max: 7.14
Current: 3.99
0.45
7.14
Days Inventory 237.57
TRIB's Days Inventory is ranked lower than
92% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. TRIB: 237.57 )
Ranked among companies with meaningful Days Inventory only.
TRIB' s Days Inventory Range Over the Past 10 Years
Min: 180.54  Med: 205.83 Max: 237.57
Current: 237.57
180.54
237.57
Days Sales Outstanding 67.20
TRIB's Days Sales Outstanding is ranked lower than
77% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. TRIB: 67.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
TRIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.9  Med: 66.84 Max: 79.08
Current: 67.2
47.9
79.08
Days Payable 58.64
TRIB's Days Payable is ranked lower than
99.99% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. TRIB: 58.64 )
Ranked among companies with meaningful Days Payable only.
TRIB' s Days Payable Range Over the Past 10 Years
Min: 41.03  Med: 66.38 Max: 111.85
Current: 58.64
41.03
111.85

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate -100.00
TRIB's 3-Year Dividend Growth Rate is ranked higher than
52% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.60 vs. TRIB: -100.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TRIB' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 30.1
Current: -100
0
30.1
5-Year Yield-on-Cost % 2.01
TRIB's 5-Year Yield-on-Cost % is ranked higher than
67% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. TRIB: 2.01 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TRIB' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.72  Med: 1.05 Max: 2.33
Current: 2.01
0.72
2.33

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 6.12
TRIB's Price-to-Tangible-Book is ranked higher than
58% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. TRIB: 6.12 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TRIB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.59  Med: 3.33 Max: 20.83
Current: 6.12
0.59
20.83
Price-to-Intrinsic-Value-Projected-FCF 3.56
TRIB's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
77% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. TRIB: 3.56 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TRIB' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.28  Med: 1.19 Max: 4.33
Current: 3.56
0.28
4.33
Price-to-Median-PS-Value 0.64
TRIB's Price-to-Median-PS-Value is ranked higher than
80% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. TRIB: 0.64 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TRIB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 0.79 Max: 2.51
Current: 0.64
0.09
2.51
Earnings Yield (Greenblatt) % -12.94
TRIB's Earnings Yield (Greenblatt) % is ranked higher than
78% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. TRIB: -12.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TRIB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -12.94  Med: 5.7 Max: 84.7
Current: -12.94
-12.94
84.7
Forward Rate of Return (Yacktman) % -11.49
TRIB's Forward Rate of Return (Yacktman) % is ranked lower than
92% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. TRIB: -11.49 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TRIB' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -32.4  Med: -2.4 Max: 2.5
Current: -11.49
-32.4
2.5

More Statistics

Revenue (TTM) (Mil) $99.61
EPS (TTM) $ -4.40
Beta1.28
Short Percentage of Float2.80%
52-Week Range $5.20 - 13.68
Shares Outstanding (Mil)23.10

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.29
EPS without NRI ($) 0.29
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for TRIB

Headlines

Articles On GuruFocus.com
Trinity Biotech plc to Announce First Quarter Fiscal Year 2017 Financial Results Apr 18 2017 
Zeke Ashton Sells Greenlight Capital and Vector Group, Buys Parker and Alphabet Nov 23 2015 

More From Other Websites
Investor Network: Trinity Biotech Plc Sponsored ADR Class A to Host Earnings Call Apr 27 2017
Trinity Biotech Announces Results for Q1, 2017 Apr 27 2017
Trinity Biotech plc to Announce First Quarter Fiscal Year 2017 Financial Results Apr 18 2017
Edited Transcript of TRIB earnings conference call or presentation 14-Mar-17 3:00pm GMT Mar 14 2017
Trinity Biotech announces Quarter 4 and Fiscal Year 2016 Financial Results Mar 14 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Trinity Biotech plc... Mar 01 2017
INVESTOR ALERT: Glancy Prongay & Murray Commences Investigation on Behalf of Trinity Biotech plc... Mar 01 2017
Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2016 Financial Results Feb 24 2017
Bragar Eagel & Squire, P.C. Is Investigating Trinity Biotech plc (TRIB) on Behalf of Stockholders... Jan 05 2017
Is BioSpecifics Technologies Corp. (BSTC) A Good Stock To Buy Right Now? Dec 15 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities... Oct 31 2016
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Trinity Biotech plc and... Oct 19 2016
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Trinity Biotech plc and... Oct 06 2016
INVESTOR ALERT: Investigation of Trinity Biotech plc Announced by Law Offices of Howard G. Smith Oct 06 2016
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Trinity Biotech plc and Advises... Oct 05 2016
TRINITY NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Oct 05 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities... Oct 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)